Peptide Compounding at Westmoreland Pharmacy
Availability updates and prescription information for patients and healthcare providers
Westmoreland Pharmacy is evaluating select peptides for patient-specific compounding. If you’re a patient with questions about a peptide you’ve heard about, or a prescriber checking whether we can prepare a specific medication, our pharmacy team can help you understand the next step.
What’s happening with peptide availability?
The U.S. Department of Health and Human Services (HHS) announced an interim enforcement discretion policy in October 2026 covering six peptide ingredients under specified conditions. The ingredients named in the policy are BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax.
Westmoreland is reviewing which preparations it may be able to offer. Contact us to confirm current availability for a specific preparation before sending a prescription.
Compounded medications do not have FDA approval. The interim HHS policy is subject to change.
What is a compounded peptide?
Peptides are short chains of amino acids. A compounded peptide medication is prepared by a compounding pharmacy for an individual patient when a prescriber determines that a compounded preparation is appropriate. Evidence and risks vary by peptide and intended use.
For Patients
Start with your healthcare provider
If you’re interested in a specific peptide, ask your healthcare provider about the evidence for your condition, potential risks, and other treatment options. If your provider determines that a compounded preparation is appropriate, they can contact Westmoreland to discuss availability and prescription requirements.
For Prescribers
Confirm the preparation before prescribing
Contact our compounding team to discuss a specific peptide, its intended route of administration, and any available strengths or dosage forms. We can confirm whether we can prepare it for your patient, what information the prescription requires, and whether we can dispense it in the patient’s state.
Peptides We’re Evaluating
Westmoreland Pharmacy is evaluating select peptides for patient-specific compounding under the interim HHS enforcement discretion policy. The four peptides below are among those named in the policy. Explore what researchers are studying, and contact our pharmacy team to confirm current availability before sending a prescription.
BPC-157
Research focus · Tissue repair and inflammation
Researchers have studied BPC-157 in tendon injury and gastrointestinal inflammation.
TB-500
Research focus · Cell movement and tissue repair
TB-500 is a fragment of thymosin beta-4, a protein studied for its role in cell movement and tissue repair.
KPV
Research focus · Inflammatory signaling
KPV is a peptide made up of three amino acids. Laboratory and animal studies have explored how it affects inflammatory signaling, including in models of skin and intestinal inflammation.
MOTS-c
Research focus · Cellular energy and metabolism
MOTS-c is a peptide associated with mitochondria, the structures in cells that help produce energy. Early research has examined its role in energy use and glucose metabolism.
These research summaries describe areas of study. Compounded peptide preparations do not have FDA approval, and early findings do not establish safety or effectiveness for a particular condition. Any preparation Westmoreland offers requires a valid, patient-specific prescription.
Explore Sermorelin
Sermorelin is a synthetic peptide that stimulates the pituitary gland to release growth hormone. Evidence supporting its use for healthy aging or general wellness remains limited. Visit our dedicated page to learn more and contact our pharmacy team with questions about compounded formulations.
Westmoreland’s Approach to Peptide Compounding
Westmoreland Pharmacy is accredited by the Pharmacy Compounding Accreditation Board (PCAB), a service of ACHC, and provides sterile and nonsterile compounding. Our team includes board-certified sterile compounding pharmacists.
As we evaluate peptide preparations, our focus includes:
Ingredient qualification
Review ingredient sources and supplier documentation against applicable requirements.
Preparation-specific quality controls
Determine which quality checks and testing are required for each formulation and route of administration.
Prescription and dispensing requirements
Confirm that a preparation can be compounded for the individual patient and dispensed in the patient’s state.
Prescriber support
Help healthcare providers confirm availability, discuss formulation options, and understand what to include on a prescription.
Frequently Asked Questions
Do I need a prescription?
Yes. Westmoreland requires a valid prescription for an individual patient before preparing a compounded peptide medication.
Can I use a peptide sold online for research?
Products labeled for research use only are intended for research. Ask your healthcare provider about medication options for your care.
Does the HHS policy mean the FDA has approved these preparations?
The HHS policy describes how the department intends to exercise enforcement discretion under specific conditions. Compounded preparations do not have FDA approval, and the FDA does not review their safety, effectiveness, or quality before marketing.
When will compounded peptides be available from Westmoreland Pharmacy?
Westmoreland Pharmacy is evaluating select peptides for patient-specific compounding, including BPC-157, TB-500, KPV, and MOTS-c. Our team is reviewing ingredient sourcing, formulation requirements, and the quality checks needed for each preparation based on HHS requirements and our own high standards.
We’re still determining which preparations we can offer and when. Sign up for peptide updates to hear from us as availability is confirmed.
How much will compounded peptides cost?
Pricing is still being determined. The cost of each preparation will depend on ingredient sourcing, formulation, and testing requirements. We’ll share pricing information with patients and prescribers once it’s finalized.
Get Peptide Availability Updates
Sign up for email updates from Westmoreland Pharmacy about peptide availability and changes that may affect patients and prescribers.
Latest Peptide Updates & Articles

HHS Peptide Compounding Update: What Patients and Providers Should Know
A recent announcement from the U.S. Department of Health and Human Services (HHS) could change access to certain compounded